Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAquis Exchange Regulatory News (AQX)

  • This share is currently suspended. It was suspended at a price of 725.00
  • There is currently no data for AQX

Block Listing Six Monthly Return

19 May 2025 11:02

RNS Number : 2256J
Aquis Exchange PLC
19 May 2025
Β 

BLOCK LISTING SIX MONTHLY RETURN

Β 

INFORMATION PROVIDED ON THIS FORM MUST BE TYPED OR PRINTED ELECTRONICALLY AND PROVIDED TO A PIP.

Β 

(Note: Italicised terms have the same meaning as given in the UK Listing Rules.)

Date: 19 MAY 2025

Β 

Name of applicant:

Aquis Exchange Plc

Name of scheme:

2020 EMI Option Scheme

Period of return:

From:

18/11/2024

To:

19/05/2025

Balance of unallotted securities under scheme(s) from previous return:

505,917 ordinary shares of 10p each.

Plus:Β  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:Β  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

38,750 ordinary shares of 10p each

Equals:Β  Balance under scheme(s) not yet issued/allotted at end of period:

467,167 ordinary shares of 10p each.

Β 

Name of contact:

Philip Olm

Telephone number of contact:

+44 2035 976 375

Β 

Β 

Enquiries:

Β 

Aquis Exchange PLC

David Stevens, CEO

Richard Fisher, CFO

Adele Gilbert, Head of Marketing & Investor Relations

Β 

Tel: +44 (0)20 3597 6329

investorrelations@aquis.eu

Investec Bank plcΒ (Nominated Adviser and Broker)

David Anderson

St John Hunter

Β 

Tel: +44 (0)20 7597 5970

Canaccord Genuity LimitedΒ (Joint Broker)

Emma Gabriel

George GraingerΒ 

Β 

Β Tel: +44 (0) 20 7523 8000

Β 

VSA Capital LimitedΒ (AQSE Corporate Adviser)

Andrew Raca

Β 

Tel: +44 (0) 20 3005 5000

Β 

Β 

About Aquis Exchange PLC

Aquis Exchange PLC ("Aquis") is Europe's challenger exchange, creating better markets for a modern economy. Aquis has market-leading technology and innovative rules for trading, and offer primary listings and secondary trading of equities, along with global licensing of proprietary technology.

Aquis consists of four divisions:

Aquis MarketsΒ operates lit and dark order books, covering 16 European markets. For its lit books, Aquis uses a subscription pricing model which works by charging users according to the message traffic they generate, rather than a percentage of the value of each stock that they trade.

Aquis TechnologiesΒ is the software and technology division of Aquis. It focuses on building better markets via the creation and licensing of cutting-edge, cost-effective exchange infrastructure technology and services, including matching engine and trade surveillance solutions.

Aquis Stock ExchangeΒ (AQSE) is a stock market providing primary and secondary markets for equity and debt products. It is authorised as a Recognised Investment Exchange, which allows it to operate a regulated listings venue. The AQSE Growth Market is divided into two segments 'Access' and 'Apex'; the Access market focuses on earlier stage growth companies, while Apex is the intended market for larger, more established businesses.

Aquis DataΒ generates revenue from the sale of data derived fromΒ Aquis MarketsΒ and Aquis Stock Exchange to non-Member market participants.

Aquis is authorised and regulated by the UK Financial Conduct Authority and France'sΒ AutoritΓ© de contrΓ΄le prudentiel et de rΓ©solutionΒ and L'AutoritΓ© des marchΓ©s financiers to operate Multilateral Trading Facility businesses in the UK & Switzerland markets and in EU27 markets respectively. Aquis Exchange PLC is quoted on the Aquis Stock Exchange and on the AIM Market (AIM) of the LSE. For more information, please go toΒ www.aquis.eu.

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BLRALMLTMTABMLA
Date   Source Headline
4th Apr 20227:00 amRNSDirector/PDMR Dealing
1st Apr 20223:53 pmRNSTransfer of UBS MTF Business Activities Completed
30th Mar 20229:35 amRNSExercise of Share Options and Total Voting Rights
29th Mar 20227:10 amRNSFinal Results and Board Appointments
29th Mar 20227:00 amRNSAdmission to Trading on the AQSE Growth Market
16th Mar 20227:00 amRNSTransfer of UBS MTF business activities to Aquis
11th Mar 20227:00 amRNSIntention to Dual List on the AQSE
24th Feb 20227:00 amRNSNotice of Results
8th Feb 20227:00 amRNSAquis Technologies partners with Investre
26th Nov 20219:48 amRNSExercise of Share Options and Total Voting Rights
26th Nov 20217:00 amRNSAppointment of New Chair
25th Nov 20217:00 amRNSDirector/PDMR Notification
23rd Sep 20215:39 pmRNSExercise of Share Options, Director Dealing & TVR
23rd Sep 20217:00 amRNSInterim Results
17th Sep 20217:00 amRNSBoard Appointment
1st Sep 20217:00 amRNSNotice of Results
25th Aug 20217:00 amRNSAppointment of independent NED to AQSE Board
2nd Aug 20217:00 amRNSAquis Exchange achieves record market share
28th Jun 20214:21 pmRNSExercise of Share Options and Director Dealing
27th May 20217:00 amRNSAQSE expands research for its top-tier stocks
18th May 20217:00 amRNSDual quotations with the Frankfurt Stock Exchange
13th May 20217:00 amRNSNew Senior Management Appointments
30th Apr 20217:00 amRNSDirector/PDMR Notification & Issue of Options
27th Apr 202112:41 pmRNSResult of Annual General Meeting
8th Apr 20217:00 amRNSDirector/PDMR Notification
31st Mar 20214:51 pmRNSPublication of ARA and Notice of AGM
31st Mar 20217:00 amRNSFinal Results
26th Mar 20217:00 amRNSNotice of Results
24th Mar 20217:00 amRNSAquis Exchange and ShareSoc Retail Investor Survey
26th Feb 20217:00 amRNSTrading and Operational Update
5th Feb 202112:07 pmRNSAppointment of Joint Broker
4th Feb 20218:03 amRNSAquis Exchange recommences trading in Swiss shares
14th Dec 20207:00 amRNSAQSE rule changes & market segments now in effect
26th Nov 20207:00 amRNSDirector/PDMR Notification
23rd Nov 20207:00 amRNSAQSE launches Market Maker Incentive Scheme
20th Nov 20202:00 pmRNSAquis works with SGX & AWS on cloud deployment
19th Oct 20207:00 amRNSAppointment to the AQSE Board
12th Oct 20207:00 amRNSAppointment of Independent Non-executive Director
9th Sep 20207:00 amRNSInterim Results
27th Aug 20207:00 amRNSNotice of Results
17th Jun 20207:00 amRNSBoard Appointment
16th Jun 20207:00 amRNSHolding(s) in Company
15th Jun 20207:01 amRNSDirector/PDMR Notification
15th Jun 20207:00 amRNSIssue of Options and Director/PDMR Notification
19th May 20201:26 pmRNSResult of Annual General Meeting
24th Apr 20207:00 amRNSPublication of ARA and Notice of AGM
20th Apr 20207:00 amRNSIssue of Options and Director/PDMR Notification
16th Apr 20207:00 amRNSFinal results
15th Apr 20207:00 amRNSExercise of Share Options & Total Voting Rights
24th Mar 20207:00 amRNSUpdate to Results Announcement Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.